Unaudited Pro Forma Condensed Combined Balance Sheet. The following adjustments were made in the preparation of the Unaudited Pro Forma Condensed Combined Balance Sheet as of March 31, 2023:
Unaudited Pro Forma Condensed Combined Balance Sheet. June 30, 2017 (dollars in millions, except per share data) Catalent Cook Pharmica Financing Transactions Acquisition Pro Forma ASSETS Current assets: Cash and cash equivalents $ 288.3 $ — $ 683.6 (a) $ (760.4 )(b) $ 211.5 Trade receivables, net 488.8 32.9 — — 521.7 Inventories 184.9 16.2 — — 201.1 Prepaid expenses and other 97.8 2.0 — — 99.8 Total current assets 1,059.8 51.1 683.6 (760.4 ) 1034.1 Property, plant, and equipment, net 995.9 171.7 — 63.0 (c) 1,230.6 Other assets: Goodwill 1,044.1 — — 408.7 (d) 1,452.8 Other intangibles, net 273.1 — — 260.0 (e) 533.1 Deferred income taxes 53.9 110.6 — (110.6 )(f) 53.9 Other 27.5 — — — 27.5 Total assets $ 3,454.3 $ 333.4 $ 683.6 $ (139.3 ) $ 4,332.0 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current portion of long-term obligations and other short-term borrowings $ 24.6 $ — $ — $ 48.4 (g) $ 73.0 Accounts payable 163.2 4.9 — — 168.1 Other accrued liabilities 281.2 18.6 (h) — — 299.8 Total current liabilities 469.0 23.5 — 48.4 540.9 Long-term obligations, less current portion 2,055.1 — 441.5 (i) 134.5 (g) 2,631.1 Pension liability 129.5 — — — 129.5 Deferred income taxes 31.7 — — — 31.7 Other liabilities 45.5 0.1 (h) — — 45.6 Shareholders’ equity/(deficit): Common stock $0.01 par value; 1.0 billion shares authorized, actual, as adjusted, and pro forma; 125,049,867 shares issued and outstanding, actual; 131,179,867 shares issued and outstanding, as adjusted and pro forma 1.3 — 0.1 (j) — 1.4 Preferred stock $0.01 par value; 100 million authorized, actual, adjusted, and pro forma; 0 issued and outstanding, actual, as adjusted, and pro forma — — — — — Additional paid in capital 1,992.0 — 242.0 (j) — 2,234.0 Accumulated deficit (955.7 ) (163.9 ) — 151.5 (j),(k) (968.1 ) Net parent investment — 473.7 — (473.7 )(k) — Accumulated other comprehensive income/(loss) (314.1 ) — — — (314.1 ) Total shareholders’ equity 723.5 309.8 242.1 (322.2 ) 953.2 Total liabilities and shareholders’ equity $ 3,454.3 $ 333.4 $ 683.6 $ (139.3 ) $ 4,332.0 See accompanying notes to unaudited pro forma condensed combined financial statements.
Unaudited Pro Forma Condensed Combined Balance Sheet. (A) Sources and Uses (in millions) Sources of funds: Express Scripts cash on hand at September 30, 2011 $ 1,000.0 Term Loan Facility 4,000.0 Existing New Express Scripts Notes 4,086.3 Additional debt financing 4,429.6 Total sources of funds $ 13,515.9 Use of funds: Cash payments to Medco stockholders $ 11,158.9 Payment of Medco 2012 term loan and revolving credit facility due 2013 2,000.0 Express Scripts transaction costs(1) 209.7 New debt issuance costs(2) 147.3 Total use of funds $ 13,515.9
Unaudited Pro Forma Condensed Combined Balance Sheet. The unaudited pro forma condensed combined balance sheet give effect to the following pro forma adjustments:
Unaudited Pro Forma Condensed Combined Balance Sheet. China VTV Limited, a Nevada Corporation China VTV Limited, a Hong Kong Company February 28, 2019 February 28, 2019 Pro FormaAdjustment Note CombinedPro Forma ASSETS Current Assets Cash and cash equivalents $ 17,548 $ - $ 17,548 Total Current Assets 17,548 - - 17,548 Total Assets $ 17,548 $ - $ - $ 17,548 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current Liabilities Accrued expenses $ 23,163 $ - $ - $ 23,163 Due to related parties 456,474 136,265 - 592,739 Total Current Liabilities 479,637 136,265 - 615,902 Total Liabilities 479,637 136,265 - 615,902 Stockholders’ deficit Common Stock 105,000 128,982 (18,432 ) (1) 215,550 Additional paid-in capital 10,663 2,072,683 18,432 (1) 1,524,026 (577,752 ) (2) Accumulated deficit (577,752 ) (2,337,167 ) 577,752 (2) (2,337,167 ) Other comprehensive loss (763 ) (763 ) Total Stockholders’ Deficit (462,089 ) (136,265 ) - (598,354 ) Total Liabilities and Stockholders’ Deficit $ 17,548 $ - $ - $ 17,548 CHINA VTV LIMITED AND SUBSIDIARY UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME(LOSS) China VTV Limited, a Nevada Corporation China VTV Limited, a Hong Kong Company For the Twelve For the Twelve Months ended Months ended February 28,2019 February 28,2019 Pro FormaAdjustment Note CombinedPro Forma Revenues $ - $ - - $ - Cost of revenues - - - - Gross profit - - - - Operating expenses Research and development expenses - 861,581 - 861,581 General and administrative expenses 90,587 13,426 - 104,013 Total operating expenses 90,587 875,007 - 965,594 Loss from operations (90,587 ) (875,007 ) - (965,594 ) Loss before provision for income tax (90,587 ) (875,007 ) - (965,594 ) Provision for income tax (benefit) - - - - Net loss (90,587 ) (875,007 ) - (965,594 ) Other Comprehensive Income (Loss): Foreign currency translation adjustment, net of tax - (37 ) (37 ) Comprehensive Loss $ (90,587 ) $ (875,044 ) $ - $ (965,631 ) Net loss per share attributable to common stockholders Basic and diluted $ (0.00 ) $ (0.00 ) Weighted average number of common shares outstanding Basic and diluted 92,950,820 (3) 269,649,590
Unaudited Pro Forma Condensed Combined Balance Sheet. A-Cash and cash equivalents This adjustments reflects the $250 million purchase price, offset by the $100 million draw on the Company's revolving line of credit (see notes E and I below for a discussion of the adjustments to record the liability for the draw on the revolving credit line and associated interest expense).
Unaudited Pro Forma Condensed Combined Balance Sheet. (1) The reclassification of $159,329 of accrued expenses from accounts payable and accrued expenses.
Unaudited Pro Forma Condensed Combined Balance Sheet. As of December 31, 2019 (In thousands) Sonnet BioTherapeutics, Inc. Relief Therapeutics SA Pro Forma Adjustments Notes Pro Forma Sonnet BioTherapeutics, Inc. Reverse Recapitalization Notes Pro Forma Combined Assets Current assets: Cash and cash equivalents $ 889 $ 9 $ 1,355 A $ 2,253 $ 9,000 E $ 11,253 Related party receivable — 1,027 — 1,027 — 1,027 Prepaid expenses and other current assets 20 27 — 47 — 47 Total current assets 909 1,063 1,355 3,327 9,000 12,327 Property and equipment $ 48 $ — — 48 $ — 48 Total assets $ 957 $ 1,063 $ 1,355 $ 3,375 $ 9,000 $ 12,375 Liabilities and stockholders’ equity (deficit) Current liabilities: Related-party notes $ 1 $ — $ — $ 1 $ — $ 1 Accounts payable 3,207 56 (56 ) D 3,207 — 3,207 Other accrued expenses 148 142 — 290 1,042 F 1,332 Total current liabilities 3,356 212 (56 ) 3,512 1,042 4,554 Defined benefit obligation — 138 (138 ) C — — — Total liabilities 3,356 350 (194 ) 3,512 1,042 4,554 Stockholders’ equity (deficit): Common stock 12,510 212 16,980 A,B 29,702 (29,701 ) G 1 Additional paid-in capital — 607 (607 ) B — 42,701 G 42,701 Accumulated deficit (14,909 ) (106 ) (14,824 ) B (29,839 ) (5,042 ) G (34,881 ) Total stockholders’ equity (deficit) (2,399 ) 713 1,549 (137 ) 7,958 7,821 Total liabilities and stockholders’ equity $ 957 $ 1,063 $ 1,355 $ 3,375 $ 9,000 $ 12,375
Unaudited Pro Forma Condensed Combined Balance Sheet. As of September 30, 2021 Note A Derived from the unaudited condensed consolidated balance sheet of Kubient as of September 30, 2021. Note B Derived from the unaudited condensed balance sheet of MediaCrossing as of September 30, 2021 included elsewhere in this Current Report.
Unaudited Pro Forma Condensed Combined Balance Sheet. As of September 30, 2022 The following pro forma adjustments give effect to the business combination. Note A Derived from the unaudited condensed consolidated balance sheet of MICT as of September 30, 2022, which are incorporated by reference into this filing. Note B Derived from the unaudited condensed consolidated balance sheet of Tingo as of September 30, 2022, which are incorporated by reference into this filing. Adjustments:
